New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma

被引：0
|
作者：
Saillant, Arnaud [1 ]
Borchiellini, Delphine [2 ]
机构：
[1] Ctr Hosp Univ Poitiers, Dept Oncol Med, F-86021 Poitiers, France
[2] Univ Cote dAzur, Dept Oncol Med, Ctr Antoine Lacassagne, Nice, France
来源：
BULLETIN DU CANCER | 2022年 / 109卷 / 7-8期
关键词：
Carcinoma renal cell; Antineoplastic Agents; Antibodies Monoclonal; Immunotherapy;
D O I：
10.1016/j.bulcan.2022.03.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：737 / +
页数：2
相关论文
共 50 条
  • [1] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert
    Alekseev, Boris
    Rha, Sun-Young
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Kopyltsov, Evgeny
    Mendez-Vidal, Maria J.
    Kozlov, Vadim
    Alyasova, Anna
    Hong, Sung-Hoo
    Kapoor, Anil
    Alonso Gordoa, Teresa
    Merchan, Jaime R.
    Winquist, Eric
    Maroto, Pablo
    Goh, Jeffrey C.
    Kim, Miso
    Gurney, Howard
    Patel, Vijay
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Melichar, Bohuslav
    Rolland, Frederic
    De Giorgi, Ugo
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Dutcus, Corina E.
    Smith, Alan D.
    Dutta, Lea
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing, Dongyuan
    Choueiri, Toni K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14): : 1289 - 1300
  • [2] Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2021, 206 (06): : 1518 - 1519
  • [3] Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma
    Hindie, Elif
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03): : 287 - 287
  • [4] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [5] Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
    Ged, Yasser
    Lee, Chung-Han
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1049 - 1059
  • [6] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [7] New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer
    De Jesus, Clara
    Rodrigues, Manuel
    [J]. BULLETIN DU CANCER, 2022, 109 (7-8) : 740 - 741
  • [8] Lenvatinib plus Pembrolizumab in advanced Endometrial Carcinoma
    Lorenz, Judith
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (05) : 464 - 464
  • [9] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Mathew
    Stepan, Daniel E.
    Shumaker, Robert
    Schmidt, Emmett V.
    Guo, Matthew
    Dutcus, Corina
    Young, Louise
    Motzer, Robert
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 175
  • [10] LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Voss, Martin H.
    Plimack, Elizabeth R.
    Gurney, Howard
    Song, Yue
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian, I
    [J]. FUTURE ONCOLOGY, 2023, 19 (40) : 2631 - 2640
12345